Mirtazapin Actavis (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Actavis, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as an oral dosage form for oral use. It is indicated for the treatment of major depressive disorder in adult patients. GNH USA supplies Mirtazapin Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapin Actavis, a NaSSA antidepressant, is used within the depressive disorder therapeutic pathway. - Major depressive disorder: improves mood, sleep quality and appetite in adults. - Major depressive disorder (adjunctive therapy): enhances response when first‑line agents are insufficient. - Major depressive disorder (maintenance): helps sustain remission and prevent relapse.

Mirtazapin Actavis may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Suicidal thoughts or behavior, especially early in treatment - Serotonin syndrome when combined with other serotonergic agents - Hepatotoxicity in rare cases

Before initiating therapy, clinicians should consider several safety aspects. - Psychiatric assessment: evaluate baseline mood and suicidal risk. - Hepatic function: adjust use in patients with moderate to severe liver impairment. - Elderly patients: monitor for excessive sedation and falls. - Discontinuation: avoid abrupt cessation to reduce withdrawal phenomena. - Concomitant CNS depressants: use cautiously due to additive sedation. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mirtazapin Actavis can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis; a washout period is required. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential for serotonin syndrome. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma concentrations.

Moderate Interactions (Monitor Closely): - Central nervous system depressants (alcohol, benzodiazepines): additive sedation and respiratory depression. - Antihistamines: increased drowsiness. - Anticholinergic drugs: may exacerbate constipation and dry mouth.